CN114732844B - Bionic membrane composition capable of immediately relaxing and preparing method thereof - Google Patents
Bionic membrane composition capable of immediately relaxing and preparing method thereof Download PDFInfo
- Publication number
- CN114732844B CN114732844B CN202111323299.0A CN202111323299A CN114732844B CN 114732844 B CN114732844 B CN 114732844B CN 202111323299 A CN202111323299 A CN 202111323299A CN 114732844 B CN114732844 B CN 114732844B
- Authority
- CN
- China
- Prior art keywords
- sodium hyaluronate
- percent
- rhamnose
- membrane composition
- immediate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 239000012528 membrane Substances 0.000 title claims abstract description 45
- 239000011664 nicotinic acid Substances 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 19
- 230000002040 relaxant effect Effects 0.000 title description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 57
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 50
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 50
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 50
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 37
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims abstract description 33
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 claims abstract description 23
- 229930015582 oxymatrine Natural products 0.000 claims abstract description 23
- 239000008213 purified water Substances 0.000 claims abstract description 23
- 235000011187 glycerol Nutrition 0.000 claims abstract description 21
- 241001474374 Blennius Species 0.000 claims abstract description 19
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 17
- 230000001954 sterilising effect Effects 0.000 claims abstract description 17
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 16
- 239000011159 matrix material Substances 0.000 claims abstract description 12
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 11
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 9
- 208000026935 allergic disease Diseases 0.000 claims abstract description 9
- 230000007815 allergy Effects 0.000 claims abstract description 8
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims description 35
- 238000003756 stirring Methods 0.000 claims description 18
- 206010070834 Sensitisation Diseases 0.000 claims description 15
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 13
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 13
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 13
- 230000003592 biomimetic effect Effects 0.000 claims description 13
- 230000008313 sensitization Effects 0.000 claims description 13
- 239000003242 anti bacterial agent Substances 0.000 claims description 12
- 229940088710 antibiotic agent Drugs 0.000 claims description 12
- 239000011259 mixed solution Substances 0.000 claims description 12
- 229920001282 polysaccharide Polymers 0.000 claims description 11
- 239000005017 polysaccharide Substances 0.000 claims description 11
- 150000004676 glycans Chemical class 0.000 claims description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 8
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 229940072056 alginate Drugs 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 238000007599 discharging Methods 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 150000008265 rhamnosides Chemical group 0.000 claims description 6
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920002125 Sokalan® Polymers 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 4
- 241001071795 Gentiana Species 0.000 claims description 3
- 239000000043 antiallergic agent Substances 0.000 claims description 3
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 claims description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 claims description 2
- 241001369613 Stephania tetrandra Species 0.000 claims description 2
- 229930014456 matrine Natural products 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- -1 alginate oligosaccharides Chemical class 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 22
- 208000010668 atopic eczema Diseases 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 8
- 230000000172 allergic effect Effects 0.000 abstract description 4
- 239000005556 hormone Substances 0.000 abstract description 3
- 229940088597 hormone Drugs 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000002674 ointment Substances 0.000 abstract description 2
- 239000007921 spray Substances 0.000 abstract description 2
- 238000004945 emulsification Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 11
- 206010012434 Dermatitis allergic Diseases 0.000 description 8
- 201000008937 atopic dermatitis Diseases 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 2
- 229940043234 carbomer-940 Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- PGLIUCLTXOYQMV-UHFFFAOYSA-N Cetirizine hydrochloride Chemical compound Cl.Cl.C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PGLIUCLTXOYQMV-UHFFFAOYSA-N 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940126573 antibacterial therapeutic Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000010288 cold spraying Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a bionic membrane composition for immediate allergy, which consists of a medicine group and a medicine matrix, wherein the medicine group consists of oxymatrine, rhamnose, seaweed oligosaccharide and an anti-allergy element; the medicine matrix consists of sodium hyaluronate, purified water and glycerin. The invention also discloses a preparation method of the bionic membrane composition for immediate comfort, the bionic membrane composition has simple components and easy preparation, does not need an ointment emulsification process on the market, and simultaneously adopts damp-heat sterilization to ensure the safety of products. Solves the problems that the prior hormone medicine treatment is easy to be repeated and has great side effect; the method adopts medicines, cold spray and red light irradiation to treat the problems of high cost and long period of the allergic skin on the face.
Description
Technical Field
The invention belongs to the technical field of skin medicine preparation methods, and particularly relates to an immediate-sensitization bionic membrane composition and a preparation method of the immediate-sensitization bionic membrane composition.
Background
Allergic dermatitis of the face is quite common clinically, mainly refers to allergic inflammation of the skin of the face caused by contacting various stimulus factors, and is mainly clinically manifested by pruritus, blister, pimple and the like, and is easy to repeatedly attack, and seriously affects daily life. The pathogenesis is complex, is mainly related to factors such as diet, environment, nerves and the like, and once the disease is developed, the development speed is high, and the treatment is needed in time. The current treatment methods for allergic dermatitis of the face are: 1) The general patients purchase hormone medicine for treatment, the initial effect is obvious, but the effect can be lost after long-term use, the patient can basically not use the medicine again, the recurrence is more serious, and the side effects such as hormone face and the like can be caused. 2) Particularly serious patients can obtain better treatment effects by adopting a combined treatment scheme of medicines, cold spray and red light irradiation therapy in hospitals, can obviously improve various clinical symptoms of the patients, reduces recurrence rate, and is a good choice for clinically treating the allergic dermatitis of the face (Chen Zhenqiong, analysis of the effect of comprehensive therapy on treating the allergic dermatitis of the face [ J ]. Dermatological diseases and venereal diseases, 2018, 040 (003): 362-363). However, the method has the disadvantages of excessive cost, long treatment period and possibly other side effects after operation.
Disclosure of Invention
The invention aims to provide a bionic membrane composition for immediate allergy, which solves the problems that the existing method for treating the allergic skin on the face by adopting an excimer drug is easy to repeat and has great side effect; the problems of high cost and long period of adopting medicines, cold spraying and red light irradiation to treat the allergic skin on the face.
The invention further aims at providing a preparation method of the bionic membrane composition for immediate sensitization.
The technical scheme adopted by the invention is that the bionic membrane composition for immediate allergy comprises a medicine group and a medicine matrix, wherein the medicine group comprises oxymatrine, rhamnose, seaweed oligosaccharide and an anti-allergy element; the medicine matrix consists of sodium hyaluronate, purified water and glycerin; the weight percentage of each component is as follows: 0.05 to 0.1 percent of oxymatrine, 0.5 to 2.0 percent of rhamnose, 0.5 to 4.0 percent of seaweed oligosaccharide, 2.0 to 6.0 percent of antibiotics, 0.6 to 1.2 percent of sodium hyaluronate, 2.0 to 5.0 percent of glycerol and the balance of purified water, wherein the sum of the mass percentages of the components is 100 percent.
The present invention is also characterized in that,
rhamnose can be replaced by rhamnoside and trehalose can be replaced by algal polysaccharide.
Sodium hyaluronate may be replaced with one or more of carboxymethyl cellulose, carbomer, or alginate.
The ratio of the oxymatrine to the rhamnose is 1:10-20, and the ratio of the rhamnose to the trehalose is 1:1-2.
The sodium hyaluronate consists of two kinds of hyaluronic acid with different molecular weights, wherein the molecular weight of the macromolecular sodium hyaluronate is 1800-2200kDa, the molecular weight of the micromolecular sodium hyaluronate is 200-800kDa, and the mass ratio of the macromolecular sodium hyaluronate to the micromolecular sodium hyaluronate is 1:1.5-2.
The invention adopts another technical scheme that the preparation method of the bionic membrane composition for immediate comfort specifically comprises the following steps:
step 1: weighing the following components in percentage by mass: 0.05 to 0.1 percent of oxymatrine, 0.5 to 2.0 percent of rhamnose, 0.5 to 4.0 percent of seaweed oligosaccharide, 2.0 to 6.0 percent of antibiotics, 0.2 to 0.4 percent of macromolecular sodium hyaluronate, 0.4 to 0.8 percent of micromolecular sodium hyaluronate, 2.0 to 5.0 percent of glycerol and the balance of purified water, wherein the sum of the mass percentages of the components is 100 percent;
step 2: adding the phase A raw material into a reaction container, heating to 60-80 ℃, stirring and dissolving until the raw material is transparent, preserving heat for 10-40min, and beginning to cool;
the phase A raw material comprises 90% of purified water, macromolecular sodium hyaluronate, micromolecular sodium hyaluronate and glycerol;
step 3: when the temperature is reduced to 50-60 ℃, adding the phase B raw material into the mixed solution in the step 1, stirring to dissolve each component until the components are transparent, and preserving the heat for 10-30min;
the B phase raw material comprises matrine, rhamnose and trehalose dissolved by the residual 10% purified water;
step 4: adding the antiallergic element into the mixed solution obtained in the step 3, mixing and stirring uniformly, discharging and filling;
step 5: filling the bionic membrane composition by using a medical glass bottle, and sterilizing by using a damp-heat sterilization method to obtain the bionic membrane composition capable of being immediately and sensitively used.
The present invention is also characterized in that,
the sterilization parameters of step 5 are: 121 ℃ for 12-15min.
The biomimetic film composition has a viscosity of 100 mPa-s to 500 mPa-s.
And 2, the molecular weight of the macromolecular sodium hyaluronate is 1800-2200kDa, the molecular weight of the micromolecular sodium hyaluronate is 200-800kDa, and the mass ratio of the macromolecular sodium hyaluronate to the micromolecular sodium hyaluronate is 1:1.5-2.
Rhamnose can be replaced by rhamnoside, and the seaweed oligosaccharide can be replaced by seaweed polysaccharide; sodium hyaluronate may be replaced with one or more of carboxymethyl cellulose, carbomer, or alginate.
The beneficial effects of the invention are as follows: the bionic membrane composition for immediate allergy can treat the allergic dermatitis of the face, is designed in an omnibearing way according to a target path of the cause of the allergic dermatitis, and provides the multifunctional effects of allergy relief and inflammation resistance. The main advantages of this composition compared to the prior art are represented by the following:
(1) The bionic membrane composition is divided into a medicine group and a medicine matrix, wherein the medicine group adopts a brand new efficacy composition (oxymatrine, rhamnose, trehalose and antiallergic agent) which is not used in the skin field. Meanwhile, the effect of the antiallergic agent can achieve the effect of quickly relaxing the sensitization and removing the redness.
(2) The bionic membrane composition provided by the invention has the advantages of simple components, easiness in preparation, no need of a commercial ointment emulsifying process, and the safety of products is ensured by adopting damp-heat sterilization.
(3) The bionic membrane composition adopts the idea of a combined form of an outer membrane and an inner membrane, and takes a drug matrix as an outer membrane, so that external stimulation can be blocked, and a damaged skin barrier can be repaired; the cutin cell membrane adhered by rhamnose and trehalose is used as an inner membrane, and the damaged cell is regulated by releasing signals, so that the function of a healthy cell membrane is exerted.
Drawings
FIG. 1 (a) is a left-face front-back comparison of a volunteer 1 using a biomimetic membrane composition of the present invention that is immediate sensitization;
FIG. 1 (b) is a graph showing a comparison of the front and back of the right face of a volunteer 1 using a biomimetic membrane composition that is immediate sensitization in accordance with the present invention;
FIG. 2 (a) is a left-face front-back comparison of a biomimetic membrane composition of the present invention for immediate sensitization in volunteer 2;
FIG. 2 (b) is a graph showing a comparison of the front and back of the right face of a biomimetic membrane composition of the present invention for immediate sensitization of volunteer 2;
FIG. 3 (a) is a left-face front-back comparison of volunteer 3 using an immediate sensitization biomimetic membrane composition in accordance with the present invention;
fig. 3 (b) is a graph of a right-face front-back comparison of volunteer 3 using an immediate sensitization biomimetic membrane composition in accordance with the present invention.
Detailed Description
The present invention will be described in detail with reference to the following embodiments.
The invention relates to a bionic membrane composition for immediate allergy, which consists of a medicine group and a medicine matrix, wherein the medicine group consists of oxymatrine, rhamnose, seaweed oligosaccharide and an anti-allergy element; the medicine matrix consists of sodium hyaluronate, purified water and glycerin; the weight percentage of each component is as follows: 0.05 to 0.1 percent of oxymatrine, 0.5 to 2.0 percent of rhamnose, 0.5 to 4.0 percent of trehalose, 2.0 to 6.0 percent of antibiotics, 0.6 to 1.2 percent of sodium hyaluronate, 2.0 to 5.0 percent of glycerol and the balance of purified water, wherein the sum of the mass percentages of the components is 100 percent.
The raw materials have the following functions:
oxymatrine has anti-inflammatory effects on various acute and chronic inflammations (including immune and non-immune inflammations). Oxymatrine produces anti-inflammatory effects by inhibiting the expression of inflammatory cytokines (e.g., IL, TNF- α, antibodies, etc.) by phagocytes, lymphocytes, and injured tissue cells and up-regulating the expression of the anti-inflammatory cytokine IL-10. Oxymatrine can also inhibit prostaglandin biosynthesis, which is an inflammatory mediator, and conversion of arachidonic acid to leukotriene by inhibiting cyclooxygenase, and can also inhibit histamine release from mast cells by stabilizing cell membranes, thus producing an anti-inflammatory effect.
Rhamnose is a substance widely present in plants among polysaccharides, glycosides, plant gums and bacterial polysaccharides and is widely distributed in plants as a trace sugar. The compound is usually in the form of combined sugar and has a certain anti-inflammatory effect. The L-rhamnose used in the invention is a signal saccharide, 100% of the L-rhamnose is derived from natural plant pagodatree flower bud, has high purity of 98%, has high affinity with keratinocytes, forms a bionic membrane on a damaged cell membrane through the compatibility of the L-rhamnose and the cell membrane, can play a healthy cell membrane role by limiting the release of inflammatory signals by the keratinocytes and repairing the cell membrane, and effectively resists attack of external stimulus. In addition, rhamnose is monosaccharide obtained by hydrolyzing rhamnoside, and has better anti-inflammatory and antibacterial therapeutic effects than the form of combined glucoside.
The seaweed oligosaccharide has good water solubility and small molecular weight, and is easier to be absorbed and utilized compared with seaweed polysaccharide; in addition, the seaweed oligosaccharide has the biological activity which is not possessed by the seaweed polysaccharide, and many researches have proved that the seaweed oligosaccharide can play a positive role in the fields of plant growth regulation and stress resistance and disease resistance induction, but the seaweed oligosaccharide has not been applied to the field of skin allergy treatment. The product applies the seaweed oligosaccharide to the active pharmaceutical ingredients, and achieves the treatment effect by utilizing the water-retaining and antibacterial effects of the seaweed oligosaccharide.
The composition of the antiallergic element is a composition of stephania tetrandra and gentian, and the product can accept high temperature and meet the requirements of special process of damp-heat sterilization of the product. Meanwhile, the tetrandra and the gentian of the product have the effect of treating the allergic dermatitis of the face, and can quickly eliminate itching and stinging caused by allergy, and relieve inflammation and red swelling.
Glycerin is used as a humectant, and has the main functions of solvent and improving the product moisture retention. Meanwhile, the glycerol can also stabilize the stability of the active ingredients of the medicine.
The current application range of the sodium hyaluronate is very wide, and the sodium hyaluronate is applied to foods, cosmetics and medicines. Sodium hyaluronate is a main component constituting connective tissue such as human body cell matrix, eye vitreous body, joint synovial fluid, etc., and has the characteristics of retaining water, maintaining extracellular space, regulating osmotic pressure, lubricating, and promoting cell repair in vivo. Sodium hyaluronate is known to be used as a carrier of an ophthalmic drug, and the bioavailability of the drug can be improved by increasing the viscosity of eye drops to prolong the residence time of the drug on the surface of the eye. The irritation of the medicine to eyes is relieved. The characteristic of improving the drug performance is utilized, and the drug is used as a drug matrix to prolong the drug activity in the invention.
Example 1
A bionic membrane composition for immediate comfort and a preparation method thereof specifically comprise the following steps:
firstly, the following raw materials are weighed, and the contents of the components are as follows: 0.05% of oxymatrine, 0.5% of rhamnose, 0.5% of trehalose, 2.0% of antibiotics, 0.3% of macromolecular sodium hyaluronate, 0.6% of micromolecular sodium hyaluronate, 3.0% of glycerol and the balance of purified water, wherein the sum of the mass percentages of the components is 100%;
step 1, adding the phase A raw material into a reaction container, heating to 60 ℃, stirring and dissolving until the raw material is transparent, preserving heat for 20min, and starting to cool;
the A phase raw material comprises macromolecular sodium hyaluronate, micromolecular sodium hyaluronate, glycerol and 90.0% of purified water
Step 2: when the temperature is reduced to 50 ℃, adding the phase B raw material into the mixed solution in the step 1, stirring to dissolve each component until the components are transparent, and preserving heat for 20min;
the phase B raw material comprises 10.0% of purified water dissolved oxymatrine, rhamnose and seaweed oligosaccharide;
step 3: adding the antiallergic element into the mixed solution obtained in the step 2, mixing and stirring uniformly, discharging and filling;
step 4: filling the bionic membrane composition by using a medical glass bottle, and sterilizing by using a damp-heat sterilization method to obtain the bionic membrane composition capable of being immediately and sensitively used.
Example 2
Firstly, the following raw materials are weighed, and the contents of the components are as follows: 0.1% of oxymatrine, 2.0% of rhamnose, 4.0% of trehalose, 6.0% of antibiotics, 0.4% of macromolecular sodium hyaluronate, 0.8% of micromolecular sodium hyaluronate, 5.0% of glycerol and the balance of purified water, wherein the sum of the mass percentages of the components is 100%;
step 1, adding the phase A raw material into a reaction container, heating to 60-80 ℃, stirring and dissolving until the raw material is transparent, preserving heat for 30min, and beginning to cool;
the A phase raw material comprises macromolecular sodium hyaluronate, micromolecular sodium hyaluronate, glycerol and 90.0% of purified water.
Step 2: when the temperature is reduced to 50-60 ℃, adding the phase B raw material into the mixed solution in the step 1, stirring to dissolve each component until the components are transparent, and preserving heat for 20min;
the phase B raw material comprises 10.0% of purified water-dissolved oxymatrine, rhamnose and seaweed oligosaccharide;
step 3: adding 6.0% of the antibiotics into the mixed solution obtained in the step 2, mixing and stirring uniformly, discharging and filling;
step 4: filling the bionic membrane composition by using a medical glass bottle, and sterilizing by using a damp-heat sterilization method to obtain the bionic membrane composition capable of being immediately and sensitively used.
Example 3
Firstly, the following raw materials are weighed, and the contents of the components are as follows: 0.05% of oxymatrine, 1.5% of rhamnose, 1.0% of algal polysaccharide, 2.0% of antibiotics, 0.6% of carboxymethyl cellulose, 2.0% of glycerol and the balance of purified water, wherein the sum of the mass percentages of the components is 100%;
step 1, adding the phase A raw material into a reaction container, heating to 80 ℃, stirring and dissolving until the raw material is transparent, preserving heat for 15min, and starting to cool;
the A phase raw material comprises carboxymethyl cellulose (which can be replaced by carbomer 940 or sodium alginate), glycerol and 90% of purified water;
step 2: when the temperature is reduced to 60 ℃, adding the phase B raw material into the mixed solution in the step 1, stirring to dissolve each component until the components are transparent, and preserving heat for 25min;
the phase B raw material comprises 10.0% of purified water dissolved oxymatrine, rhamnose and algal polysaccharide;
step 3: adding 2.0% of the antibiotics into the mixed solution obtained in the step 2, mixing and stirring uniformly, discharging and filling;
step 4: filling the bionic membrane composition by using a medical glass bottle, and sterilizing by using a damp-heat sterilization method to obtain the bionic membrane composition capable of being immediately and sensitively used.
Example 4:
firstly, the following raw materials are weighed, and the contents of the components are as follows: 0.1% of oxymatrine, 2.0% of rhamnose, 2.0% of algal polysaccharide, 6.0% of antibiotics, 0.8% of carboxymethyl cellulose, 5.0% of glycerol and the balance of purified water, wherein the sum of the mass percentages of the components is 100%;
step 1, adding the phase A raw material into a reaction container, heating to 70 ℃, stirring and dissolving until the raw material is transparent, preserving heat for 40min, and starting to cool;
the A phase raw material comprises carboxymethyl cellulose (which can be replaced by carbomer 940 or sodium alginate), glycerol and 90% of purified water;
step 2: when the temperature is reduced to 55 ℃, adding the phase B raw material into the mixed solution in the step 1, stirring to dissolve each component until the components are transparent, and preserving heat for 25min;
the phase B raw material comprises 10.0% of purified water-dissolved oxymatrine, rhamnoside and trehalose;
step 3: adding 6.0% of the antibiotics into the mixed solution obtained in the step 2, mixing and stirring uniformly, discharging and filling;
step 4: filling the bionic membrane composition by using a medical glass bottle, and sterilizing by using a damp-heat sterilization method to obtain the bionic membrane composition capable of being immediately and sensitively used.
Evaluation of effectiveness of the instant allergy-relieving biomimetic film composition of the present invention:
1. full face testing
The biofilm composition of the invention (example 1) was evaluated using a random control method, selecting volunteers with allergic dermatitis on the face or seasonal allergies. The total treatment course is 3 weeks, the product is used for 2 times a day in the morning and evening, the dosage of the product is 0.5-1.0g, and the return visit is carried out on the 7 th day, the 14 th day and the 21 st day. The skin moisture content of the left and right faces of the volunteer is measured by adopting a skin moisture tester, the skin moisture content is photographed by a VISIA, and the effect of the red area of the product is analyzed.
a. The immediate sensitization effect of the product is evaluated (10 min-60 min).
The capsaicin tingling method is adopted to stimulate and cause itching to the volunteer, after the volunteer has obvious tingling and itching feeling, the product is smeared, the using amount of the product is 0.5-1.0g, and a questionnaire star questionnaire is filled.
According to the analysis of the investigation result of the questionnaire, the product has obvious itching relieving and red removing effects on sudden allergy. The time is mostly concentrated in 10-30min.
b. Skin moisture content test: as can be seen from Table 1, the product has a remarkable effect in repairing the barrier (skin moisture content).
Table 1 skin moisture content data record
c. Red region restoration effect: from the analysis result of the red repair effect, the greater the facial red differentiation value, the greater the effective rate, and the effective rate of 100%.
TABLE 2 red zone repair effect record
From the above data, the red areas of ten volunteers were improved to some extent, and the following example figures are effect figures of volunteer 1, volunteer 2 and volunteer 3. As is apparent from fig. 1 (a) -3 (b), the red areas of three volunteers were repaired to different extents, demonstrating that the biomimetic membrane composition has a good repairing effect on improving redness caused by allergic skin.
Claims (5)
1. The bionic membrane composition for immediate allergy is characterized by comprising a medicine group and a medicine matrix, wherein the medicine group comprises oxymatrine, rhamnose, trehalose and an anti-allergic element; the medicine matrix consists of sodium hyaluronate, purified water and glycerin; the weight percentage of each component is as follows: 0.05 to 0.1 percent of oxymatrine, 0.5 to 2.0 percent of rhamnose, 0.5 to 4.0 percent of seaweed oligosaccharide, 2.0 to 6.0 percent of antibiotics, 0.6 to 1.2 percent of sodium hyaluronate, 2.0 to 5.0 percent of glycerol and the balance of purified water, wherein the sum of the mass percentages of the components is 100 percent;
the ratio of the oxymatrine to the rhamnose is 1:10-20, and the ratio of the rhamnose to the trehalose is 1:1-2;
the sodium hyaluronate consists of two kinds of sodium hyaluronate with different molecular weights, wherein the molecular weight of macromolecular sodium hyaluronate is 1800-2200kDa, the molecular weight of micromolecular sodium hyaluronate is 200-800kDa, and the mass ratio of the macromolecular sodium hyaluronate to the micromolecular sodium hyaluronate is 1:1.5-2;
the composition of the antiallergic agent is a composition of stephania tetrandra and gentian.
2. An immediate sensitization biomimetic membrane composition according to claim 1, wherein said rhamnose can be replaced with rhamnoside and said alginate oligosaccharides can be replaced with alginate polysaccharides.
3. An immediate sensitization biomimetic membrane composition according to claim 1, wherein said sodium hyaluronate is replaced by one or more of carboxymethyl cellulose, carbomer or alginate.
4. The method for preparing the immediate sensitization bionic membrane composition according to claim 1, which is characterized by comprising the following steps:
step 1: weighing the following components in percentage by mass: 0.05 to 0.1 percent of oxymatrine, 0.5 to 2.0 percent of rhamnose, 0.5 to 2.0 percent of seaweed oligosaccharide, 2.0 to 6.0 percent of antibiotics, 0.2 to 0.4 percent of macromolecular sodium hyaluronate, 0.4 to 0.8 percent of micromolecular sodium hyaluronate, 2.0 to 5.0 percent of glycerol and the balance of purified water, wherein the sum of the mass percentages of the components is 100 percent;
step 2: adding the phase A raw material into a reaction container, heating to 60-80 ℃, stirring and dissolving until the raw material is transparent, preserving heat for 10-40min, and beginning to cool;
the phase A raw material comprises 90% of purified water, macromolecular sodium hyaluronate, micromolecular sodium hyaluronate and glycerin; the molecular weight of the macromolecular sodium hyaluronate is 1800-2200kDa, the molecular weight of the micromolecular sodium hyaluronate is 200-800kDa, and the mass ratio of the macromolecular sodium hyaluronate to the micromolecular sodium hyaluronate is 1:1.5-2;
step 3: when the temperature is reduced to 50-60 ℃, adding the phase B raw material into the mixed solution in the step 1, stirring to dissolve each component until the components are transparent, and preserving heat for 10-30min;
the phase B raw materials comprise matrine, rhamnose and trehalose dissolved by using the remaining 10% of purified water;
step 4: adding the antiallergic element into the mixed solution obtained in the step 3, mixing and stirring uniformly, discharging and filling;
step 5: filling by using a medical glass bottle, and sterilizing by using a damp-heat sterilization method, wherein the sterilization parameters are as follows: 121 ℃ for 12-15min; i.e. obtaining an immediate comfort biomimetic membrane composition having a viscosity of 100 mPa-s to 500 mPa-s.
5. The method for preparing a biomimetic membrane composition for immediate sensitization according to claim 4, wherein rhamnose can be replaced by rhamnoside and the trehalose can be replaced by algal polysaccharide; the sodium hyaluronate can be replaced by one or more of carboxymethyl cellulose, carbomer or alginate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111323299.0A CN114732844B (en) | 2021-11-09 | 2021-11-09 | Bionic membrane composition capable of immediately relaxing and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111323299.0A CN114732844B (en) | 2021-11-09 | 2021-11-09 | Bionic membrane composition capable of immediately relaxing and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114732844A CN114732844A (en) | 2022-07-12 |
| CN114732844B true CN114732844B (en) | 2023-05-16 |
Family
ID=82273767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111323299.0A Active CN114732844B (en) | 2021-11-09 | 2021-11-09 | Bionic membrane composition capable of immediately relaxing and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114732844B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490715A (en) * | 2015-01-08 | 2015-04-08 | 上海圣婕化妆品有限公司 | Anti-allergy stress relief face mask essence containing saccharide isomerate and preparation method thereof |
| CN105662916A (en) * | 2016-04-07 | 2016-06-15 | 天津嘉氏堂医美科技有限公司 | Composition for repairing sebum membrane |
| CN105726366A (en) * | 2016-04-07 | 2016-07-06 | 天津嘉氏堂医美科技有限公司 | Skin lipid membrane repairing composition |
| CN107496309A (en) * | 2017-10-23 | 2017-12-22 | 合肥卡迪尔化妆品有限公司 | Antiallergic Face-protecting mask |
| CN109568220A (en) * | 2019-02-14 | 2019-04-05 | 重庆市洲仨科技发展有限公司 | A kind of compound polyphenol antiallergic essence and antiallergic essence lotion |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100862968B1 (en) * | 2007-02-21 | 2008-10-13 | 바이오스펙트럼 주식회사 | Agents for Improving Wrinkles on Skin Comprising Matrine or Its Oxidized Derivatives |
| PT3658160T (en) * | 2017-07-28 | 2021-08-26 | Isdin Sa | Use of rhamnose and derivatives thereof as antifungal agents |
-
2021
- 2021-11-09 CN CN202111323299.0A patent/CN114732844B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104490715A (en) * | 2015-01-08 | 2015-04-08 | 上海圣婕化妆品有限公司 | Anti-allergy stress relief face mask essence containing saccharide isomerate and preparation method thereof |
| CN105662916A (en) * | 2016-04-07 | 2016-06-15 | 天津嘉氏堂医美科技有限公司 | Composition for repairing sebum membrane |
| CN105726366A (en) * | 2016-04-07 | 2016-07-06 | 天津嘉氏堂医美科技有限公司 | Skin lipid membrane repairing composition |
| CN107496309A (en) * | 2017-10-23 | 2017-12-22 | 合肥卡迪尔化妆品有限公司 | Antiallergic Face-protecting mask |
| CN109568220A (en) * | 2019-02-14 | 2019-04-05 | 重庆市洲仨科技发展有限公司 | A kind of compound polyphenol antiallergic essence and antiallergic essence lotion |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114732844A (en) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO326139B1 (en) | Composition comprising a plant chemical concentrate of Echinacea purpurea and benzalkonium chloride. | |
| CA3046764A1 (en) | Compositions comprising sulfated polysaccharides | |
| CN109125107B (en) | Polypeptide composition for effectively improving and repairing facial hormone-dependent dermatitis | |
| WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
| CN106074213A (en) | Hyaluronic acid sodium gel for water optoinjection and its preparation method and application | |
| JP2021505650A (en) | Ophthalmic drug preparations and their use | |
| CN104622897A (en) | Skin moisturizer for treating skin disease and preparation method of skin moisturizer | |
| CN112656709A (en) | Skin care compositions and uses thereof | |
| US11357814B2 (en) | Application of Sarcococca vagans, Chinese medicinal ointment for treating skin disease, preparation method and application thereof | |
| CN110302223A (en) | A kind of hair nourishing liquid preparation and preparation method thereof for repairing hair follicle | |
| CN1086590C (en) | Eye drops contg. sodium hyaluronate and preparing method thereof | |
| CN110917120A (en) | Sticky antibacterial repairing material and preparation method and application thereof | |
| CN106620639A (en) | Lutein-containing compound plant eye mask with effect of supplementing eye nutrients to resist wrinkles | |
| CN114732844B (en) | Bionic membrane composition capable of immediately relaxing and preparing method thereof | |
| CN108078868B (en) | Antiallergic composition for skin care products | |
| CN115770209A (en) | Rod-shaped lithospermum ointment containing three-purple oil and preparation method thereof | |
| CN100360141C (en) | Calf-blood deprotein extract gel | |
| CA3123849A1 (en) | Strontium based compositions and formulations for pain, pruritus, and inflammation | |
| CN105193837A (en) | Cream preparation for preventing and treating joint diseases and preparation method thereof | |
| CN105327342B (en) | A kind of paste and preparation method thereof for treating skin eczema and insect dermatitis | |
| CN113876626A (en) | Composition with protective effect on skin cell damage induced by blue light and application of composition in cosmetics | |
| CN103191163B (en) | Skin wound repairing pharmaceutical composition | |
| CN111388523A (en) | Preparation for treating acne and preparation method thereof | |
| CN113842405B (en) | Application of broussonetia papyrifera root-bark extract in preparation of anti-allergic and itching-relieving medicine for skin | |
| CH690816A5 (en) | Using a partial or Vollextrates from unfermented Camellia sinensis L. for the manufacture of a medicament, a medical product, a cosmetic product or a dietary supplement product. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A biomimetic membrane composition for immediate sensitization and its preparation method Effective date of registration: 20231206 Granted publication date: 20230516 Pledgee: Xi'an Chanba Financing Guarantee Co.,Ltd. Pledgor: Xi'an Runyu Medical Technology Co.,Ltd. Registration number: Y2023610000755 |